Immatics N.V. Stock

Equities

IMTX

NL0015285941

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-21 pm EDT 5-day change 1st Jan Change
12.37 USD -0.48% Intraday chart for Immatics N.V. -4.99% +17.47%
Sales 2024 * 72.36M Sales 2025 * 63.17M Capitalization 1.27B
Net income 2024 * -114M Net income 2025 * -142M EV / Sales 2024 * 11.7 x
Net cash position 2024 * 427M Net cash position 2025 * 412M EV / Sales 2025 * 13.6 x
P/E ratio 2024 *
-10.1 x
P/E ratio 2025 *
-8.81 x
Employees 484
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.48%
1 week-4.99%
Current month+12.15%
1 month+25.97%
3 months+9.86%
6 months+24.95%
Current year+17.47%
More quotes
1 week
12.15
Extreme 12.15
13.12
1 month
10.81
Extreme 10.81
13.77
Current year
9.67
Extreme 9.67
13.77
1 year
7.15
Extreme 7.15
13.77
3 years
5.75
Extreme 5.75
16.30
5 years
0.00
Extreme 0
18.42
10 years
0.00
Extreme 0
18.42
More quotes
Managers TitleAgeSince
Founder 50 99-12-31
Director of Finance/CFO 57 20-09-30
Chief Tech/Sci/R&D Officer 49 20-05-31
Members of the board TitleAgeSince
Director/Board Member 70 20-06-30
Chairman 68 12-09-30
Director/Board Member 63 20-06-30
More insiders
Date Price Change Volume
24-06-21 12.37 -0.48% 422,642
24-06-20 12.43 -1.19% 456,034
24-06-18 12.58 -3.31% 407,248
24-06-17 13.01 -0.08% 375,947

Delayed Quote Nasdaq, June 21, 2024 at 04:00 pm EDT

More quotes
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
12.37 USD
Average target price
19.4 USD
Spread / Average Target
+56.83%
Consensus